Management of cytomegalovirus infection after liver transplantation

Liver Transplantation

Volumn 6, Issue 2, 2000, Pages 144-156

  Sampathkumar, Priya ^a   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; OKT 3; UL 36ANTI; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; DISEASE COURSE; DRUG INDUCED DISEASE; HUMAN; IMMUNIZATION; LIVER TRANSPLANTATION; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0034020974     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500060220     Document Type: Review

References (94)

1. Paya CV, Hermans PE, Washington JAD, Smith TF, Anhalt JP, Wiesner RH, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989;64:555-564.
2. Paya CV, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, et al. Cytomegalovirus hepatitis in liver transplantation: Prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989;160:752-758.
3. Demetris AJ, Lasky S, Van Thiel DH, Starzl TE, Dekker A. Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/ steroid regimen. Am J Pathol 1985;118:151-161.
4. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1997;25:314-317.
5. Stratta RJ, Shaefer MS, Markin RS, Wood RP, Kennedy EM, Langnas AN, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989;124:1443-1449.
6. Manez R, Breinig MK, Kusne S, Linden P, Kramer D, Armstrong J, et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. Transplantation 1995;59:1220-1223.
7. Sawyer MD, Mayoral JL, Gillingham KJ, Kramer MA, Dunn DL. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch Surg 1993;128:165-169.
8. van den Berg AP, Klompmaker IJ, Haagsma EB, Peeters PM, Meerman L, Verwer R, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996;10:224-231.
9. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988;10:S460-S467.
10. Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Langnas AN, Reed EC, et al. Cytomegalovirus infection and disease after liver transplantation. An overview. Dig Dis Sci 1992;37:673-688.
11. Paya CV, Wiesner RH, Hermans PE, Larson-Keller JJ, Ilstrup DM, Krom RA, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: A prospective multivariate time-dependent analysis [published erratum J Hepatol 1993;19:325]. J Hepatol 1993;18:185-195.
12. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997;103:106-113.
13. Cakaloglu Y, Devlin J, O'Grady J, Sutherland S, Portmann BC, Heaton N, et al. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation 1995; 59:40-45.
14. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997;126:275-279.
15. Falagas ME, Arbo M, Ruthazer R, Griffith JL, Werner BG, Rohrer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997;63:1595-1601.
16. McCarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993;55:1277-1282.
17. Kim WR, Badley AD, Wiesner RH, Porayko MK, Seaberg EC, Keating MR, et al. The economic impact of cytomegalovirus infection following liver transplantation. Transplantation 2000; (in press).
18. Toorkey CB, Carrigan DR. Immunohistochemical detection of an immediate early antigen of human cytomegalovirus in normal tissues. J Infect Dis 1989;160:741-751.
19. The TH, Grefte JM, van der Bij W, van Son WJ, van den Berg AP. CMV infection after organ transplantation: Immunopathological and clinical aspects. Neth J Med 1994;45:309-318.
20. Fietze E, Prosch S, Reinke P, Stein J, Docke WD, Staffa G, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994;58:675-680.
21. Mutimer DJ, Shaw J, O'Donnell K, Elias E. Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg 1997;3:506-512.
22. Portela D, Patel R, Larson-Keller JJ, llstrup DM, Wiesner RH, Steers JL, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995;171:1014-1018.
23. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123:18-26.
24. Boland GJ, Hene RJ, Ververs C, de Haan MA, de Gast GC. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993;94:306-312.
25. Badley AD, Patel R, Portela DF, Harmsen WS, Smith TF, Ilstrup DM, et al. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. J Infect Dis 1996;173:446-449.
26. Pillay D, Ali AA, Liu SF, Kops E, Sweny P, Griffiths PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 1993;56:103-108.
27. Krogsgaard K, Boesgaard S, Aldershvile J, Arendrup H, Mortensen SA, Petterson G. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. Scand J Infect Dis 1994;26:239-247.
28. Best NG, Trull AK, Tan KK, Spiegelhalter DJ, Wreghitt TG, Wallwork J. Blood cyclosporine concentrations and cytomegalovirus infection following heart transplantation. Transplantation 1995;60:689-694.
29. Lewis RM, Johnson PC, Golden D, Van Buren CT, Kerman RH, Kahan BD. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients. Transplantation 1988;45:353-359.
30. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998;65:1450-1454.
31. Moreso F, Seron D, Morales JM, Cruzado JM, Gil-Vernet S, Perez JL, et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998;12:198-205.
32. Vanrenterghem YF. Impact of new immunosuppressive agents on late graft outcome. Kidney Int Suppl 1997;63:S81-S83.
33. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49:697-702.
34. Zlabinger GJ, Stuhlmeier KM, Eher R, Schmaldienst S, Klauser R, Vychytil A, et al. Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment. J Clin Immunol 1992;12:170-177.
35. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996;61:402-406.
36. Osman HK, Peiris JS, Taylor CE, Warwicker P, Jarrett RF, Madeley CR. "Cytomegalovirus disease" in renal allograft recipients: Is human herpesvirus 7 a co-factor for disease progression? J Med Virol 1996;48:295-301.
37. Boeckh M, Boivin G. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications. Clin Microbiol Rev 1998;11:533-554.
38. Patel R, Smith TF, Espy M, Portela D, Wiesner RH, Krom RA, et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis 1995;171:1010-1014.
39. Marsano L, Perrillo RP, Flye MW, Hanto DW, Spitzer ED, Thomas JR, et al. Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis 1990;161:454-461.
40. Paya CV, Smith TF, Ludwig J, Hermans PE. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 1989;64:670-675.
41. Patel R, Klein DW, Espy MJ, Harmsen WS, Ilstrup DM, Paya CV, et al. Optimization of detection of cytomegalovirus viremia in transplantation recipients by shell vial assay. J Clin Microbiol 1995;33:2984-2986.
42. van den Berg AP, Klompmaker IJ, Haagsma EB, Scholten-Sampson A, Bijleveld CM, Schirm J, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991;164:265-270.
43. Niubo J, Perez JL, Martinez-Lacasa JT, Garcia A, Roca J, Fabregat J, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 1996;24:19-24.
44. The TH, van der Ploeg M, van den Berg AP, Vlieger AM, van der Giessen M, van Son WJ. Direct detection of cytomegalovirus in peripheral blood leukocytes - A review of the antigenemia assay and polymerase chain reaction. Transplantation 1992;54: 193-198.
45. Manez R, Kusne S, Rinaldo C, Aguado JM, St George K, Grossi P, et al. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J Infect Dis 1996;173:1072-1076.
46. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: Correlation with disease. J Gen Virol 1995;76:309-319.
47. Macartney M, Gane EJ, Portmann B, Williams R. Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods. Transplantation 1997;63:1803-1807.
48. Mazzulli T, Drew LW, Yen-Lieberman B, Jekic-McMullen D, Kohn DJ, Isada C, et al. Multicenter comparison of the Digene Hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999;37:958-963.
49. Barkholt LM, Ericzon BG, Ehrnst A, Forsgren M, Andersson JP. Cytomegalovirus infections in liver transplant patients: Incidence and outcome. Transplant Proc 1990;22:235-237.
50. Paya CV, Holley KE, Wiesner RH, Balasubramaniam K, Smith TF, Espy MJ, et al. Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: Role of immunostaining, DNA hybridization and culture of hepatic tissue. Hepatology 1990;12: 119-126.
51. Beutner KR. Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995;28:281-290.
52. Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997;176:786-789.
53. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. CMV viral load predicts relapsing CMV disease following organ transplantation. J Infect Dis 1999; (in press).
54. Rosen HR, Benner KG, Flora KD, Rabkin JM, Orloff SL, Olyaei A, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997;63:476-478.
55. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-1733.
56. Pescovitz MD Jr, Merion R, Paya C, Pirsch J, Freeman R, Engl N, et al. Valganciclovir provides ganciclovir plasma exposure similar to IV ganciclovir in transplant recipients. American Society of Transplantation, 18th Annual Scientific Meeting, Chicago, IL, May 15-19, 1999.
57. Paya CV. Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Transplant Proc 1995; 2(suppl 1):28-30.
58. Yadin O, Dewing P, Ma JP, Ettenger RB. Cytomegalovirus hyperimmune gammaglobulin downregulates in vitro T-cell responses. Transplant Proc 1996;28(suppl 2):7-8.
59. Lattuada D, Mazzei M, Meazza R, Nicolin A. Therapeutic implications of antisense oligonucleotides. Int J Clin Lab Res 1992;21:296-299.
60. Pari GS, Field AK, Smith JA. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob Agents Chemother 1995;39:1157-1161.
61. Quinnan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
62. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-1380.
63. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241.
64. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
65. Hebart H, Einsele H. Diagnosis and treatment of cytomegalovirus infection. Curr Opin Hematol 1998;5:483-487.
66. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991;114:525-531.
67. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997;11:432-437.
68. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1993; 119:984-991.
69. Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997;64:66-73.
70. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-1470.
71. Iberer F, Tscheliessnigg K, Halwachs G, Rehak P, Wasler A, Petutschnigg B, et al. Definitions of cytomegalovirus disease after heart transplantation: Antigenemia as a marker for antiviral therapy. Transpl Int 1996;9:236-242.
72. Egan JJ, Lomax J, Barber L, Lok SS, Martyszczuk R, Yonan N, et al. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients. Transplantation 1998;65:747-752.
73. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994;120:375-381.
74. Paya CV, Marin E, Keating M, Dickson R, Porayko M, Wiesner R. Solid organ transplantation: Results and implications of acyclovir use in liver transplants. J Med Virol 1993;1:123-127.
75. Hooks MA, Perlino CA, Henderson JM, Millikan WJ Jr, Kutner MH. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992;26:617-620.
76. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997;176:1135-1140.
77. Singh N, Zeevi A, Gayowski T, Marino IR. Late onset cytomegalovirus disease in liver transplant recipients: De novo reactivation in recurrent hepatitis C virus hepatitis. Transpl Int 1998;11:308-311.
78. Gomez E, Aguado S, Melon S, Martinez A, de Ona M, Cimadevilla R, et al. A prospective study of the usefulness of rapid diagnostic tests in monitoring cytomegalovirus infection in renal transplants. Transplant Proc 1992;24:2631-2633.
79. Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998;65: 1477-1481.
80. Patel R, Smith TF, Espy M, Wiesner RH, Krom RA, Portela D, et al. Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol 1994;32:1431-1434.
81. Koskinen PK, Nieminen MS, Mattila SP, Hayry PJ, Lautenschlager IT. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993;55:547-551.
82. Saliba F, Eyraud D, Samuel D, David MF, Arulnaden JL, Dussaix E, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993;25:1444-1445.
83. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.
84. Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994;58:779-785.
85. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997;25:1344-1349.
86. Nakazato PZ, Burns W, Moore P, Garcia-Kennedy R, Cox K, Esquivel C. Viral prophylaxis in hepatic transplantation: Preliminary report of a randomized trial of acyclovir and gancyclovir. Transplant Proc 1993;25:1935-1937.
87. Cohen AT, O'Grady JG, Sutherland S, Sallie R, Tan KC, Williams R. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J Med Virol 1993;40:5-9.
88. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group, [published erratum appears in Lancet 1998;351:454.] Lancet 1997;350:1729-1733.
89. Cofer JB, Morris CA, Sutker WL, Husberg BS, Goldstein RM, Gonwa TA, et al. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 1991;23:1525-1527.
90. Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Reed EC, Langnas AN, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992;127:55-63.
91. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995;60: 1357-1360.
92. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rohrer RH, Freeman R, et al. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 1994; 26(suppl 1):23-27.
93. Saliba F, Arulnaden JL, Gugenheim J, Serves C, Samuel D, Bismuth A, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: A prospective randomized controlled study. Transplant Proc 1989;21:260-262.
94. Lumbreras C, Otero JR, Herrero JA, Gomez R, Lizasoain M, Aguado JM, et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993;37:2490-2492.